Jacksonville, Florida 32224


Determination of treatment efficacy and safety of Apremilast in patients with RAS

Study summary:

The study will be a pilot study using apremilast 30mg orally twice daily, for treatment of RAS in males and females between 18 and 70 years old. Subjects will be recruited from the clinical practice of the Department of Dermatology or Division of Rheumatology at Mayo Clinic Florida. Fifteen males and females with RAS will be enrolled. The study will consist of 3 phases: a screening phase, a 16 week treatment phase and an 8 week posttreatment observational follow-up phase. The screening phase will consist of: obtaining informed consent, demographic information, medical history, inclusion and exclusion criteria, prior and concomitant medication use, adverse events; collecting vital signs and weight; performing complete physical examination and limited physical examination; obtaining hematology, serum chemistry, urinalysis, pregnancy test and providing contraception education. During the 16-week treatment phase, all subjects receive apremilast. All subjects who complete the active treatment phase are to enter the 8-week posttreatment observational follow-up phase.


Inclusion Criteria 1. Male and female subjects between 18 and 70 years of age 2. Oral ulcers that occurred at least monthly in the 6 month period prior to enrollment 3. Had at least 2 oral ulcers in the 4 weeks prior to enrollment at baseline 4. At least 3 oral ulcers during an ulcer flare 5. Patients must be candidates for systemic therapy for the treatment of oral ulcers, those that are considered unsuitable for topical therapy alone based on severity of disease, or whose oral ulcers cannot be adequately controlled with topical therapy. 6. Female premenopausal subjects must use one of the approved contraceptive options while taking apremilast and for at least 28 days after administration of the last dose of apremilast 7. Patients are able and willing to provide written informed consent after the nature of the study is fully explained. 8. No evidence of systemic disease Exclusion Criteria 1. Prior use of apremilast. 2. Use of any investigational drug within 4 weeks prior to randomization, or 5 pharmacokinetic/pharmacodynamic half-lives, if known (whichever is longer). 3. Having received concomitant immune modulating therapy 12 weeks prior to enrollment, systemic steroids 6 weeks prior to enrollment or topical steroids within 4 weeks prior to enrollment. 4. Pregnant women or breast-feeding mothers. 5. Systemic or opportunistic fungal infection. 6. Known active current or history of recurrent bacterial, viral, fungal, mycobacterial or other infections (tuberculosis and atypical mycobacterial disease, hepatitis B and C and herpes zoster, histoplasmosis, coccidiomycosis) or any major episode of infection requiring hospitalization or treatment with IV or oral antibiotics within 4 weeks of the screening phase. 7. History of positive test for, or any clinical suspicion of, human immunodeficiency virus (HIV), or congenital or acquired immunodeficiency. 8. History of depression. 9. Malignancy or history of malignancy, except for: a - treated (ie, cured) basal cell or squamous cell in situ skin carcinomas; b - treated (ie, cured) cervical intraepithelial neoplasia (CIN) or carcinoma in situ of cervix with no evidence of recurrence within the previous 5 years. 10. Other than disease under study, any clinically significant (as determined by the Investigator) cardiac, endocrinologic, pulmonary, neurologic, psychiatric, hepatic, renal, hematologic, immunologic disease, or other major disease that is currently uncontrolled. 11. Any condition, including the presence of laboratory abnormalities, which would place the subject at unacceptable risk if he/she were to participate in the study. 12. Prior history of suicide attempt at any time in the subject's life time prior to screening or randomization, or major psychiatric illness requiring hospitalization within the last 3 years. 13. Active substance abuse or a history of substance abuse within 6 months prior to screening. 14. Presence of any of the following vitamin deficiencies - B1, B2, B6, B12, vitamin C, zinc, folate, iron. 15. Celiac disease. 16. Inflammatory Bowel Disease. 17. Genital aphthous ulcers. 18. Behçet's disease. 19. History of positive patch test for allergic contact stomatitis. 20. Positive anti-endomysial or anti-gliadin antibodies. 21. A diagnosis of uveitis (current or previous). 22. Erythema nodosum-like lesions (current or previous). 23. An established diagnosis of a systemic disease (SLE, Reiter's, Sweet's and MAGIC syndrome).

Study is Available At:

Original ID:




Secondary ID:

Study Acronym:

Brief Title:

Apremilast for RAS

Official Title:

A Pilot Study Evaluating the Efficacy of Apremilast in the Treatment of Subjects With Severe Recurrent Aphthous Stomatitis (RAS)

Overall Status:


Study Phase:




Minimum Age:

18 Years

Maximum Age:

70 Years

Quick Facts

Healthy Volunteers
Oversight Has DMC
Study Is FDA Regulated
Study Is Section 801
Has Expanded Access

Study Source:

Mayo Clinic

Oversight Authority:

There was an error processing this request

Reasons Why Stopped:

Study Type:


Study Design:

Number of Arms:


Number of Groups:


Total Enrollment:


Enrollment Type:


Overall Contact Information

Official Name:Alison J Bruce
Principal Investigator
Mayo Clinic

Study Dates

Start Date:October 12, 2018
Completion Date:December 15, 2019
Completion Type:Anticipated
Primary Completion Date:September 30, 2019
Primary Completion Type:Anticipated
Verification Date:December 2018
Last Changed Date:December 6, 2018
First Received Date:September 4, 2018

Study Outcomes

Outcome Type:Secondary Outcome
Measure:Frequency of clinically significant changes in vital signs and/or laboratory findings
Time Frame:24 weeks
Safety Issues:False
Description:The frequency of clinically significant changes in vital signs and/or laboratory findings will be measured through a complete physical examination using physiological parameters, as well as hematology and serum chemistry.
Outcome Type:Secondary Outcome
Measure:Discontinuation of study participants
Time Frame:24 weeks
Safety Issues:False
Description:Number of sbjects who prematurely discontinue treatment with apremilast due to any adverse event.
Outcome Type:Secondary Outcome
Measure:Number of participants with treatment-related adverse events as assessed by CTCAE v4.0
Time Frame:24 weeks
Safety Issues:False
Description:Type, frequency, severity and relationship of the adverse events to apremilast will be assessed and reported.
Outcome Type:Primary Outcome
Measure:Improvement in duration of the remission period between ulcer episodes
Time Frame:up to 24 weeks
Safety Issues:False
Description:Improvement in duration of the remission period between ulcer episodes will be used to factor the improvement of RAS lesions.
Outcome Type:Primary Outcome
Measure:Percentage change in number of RAS lesions
Time Frame:up to 24 weeks
Safety Issues:False
Description:The percentage change in the number of oral ulcers will be used to factor the improvement of RAS lesions.
Outcome Type:Primary Outcome
Measure:Improvement in duration of RAS lesions
Time Frame:up to 24 weeks
Safety Issues:False
Description:Improvement in the duration of oral ulcers will be used to factor the improvement of RAS lesions.

Study Interventions

Intervention Type:Drug
Name:Apremilast 30mg
Description:Apremilast is an oral small-molecule inhibitor of phosphodiesterase (PDE) 4 that works intracellularly to modulate a network of pro-inflammatory and anti-inflammatory mediators. PDE 4 is a cyclic adenosine monophosphate (cAMP)-specific PDE and the dominant PDE in inflammatory cells. PDE4 inhibition elevates intracellular cAMP levels, which in turn down-regulates the inflammatory response by modulating the expression of TNF-alfa, IL-23, IL-17 and other inflammatory cytokines. Cyclic AMP also modu
Arm Name:Single Arm

Study Arms

Study Arm Type:Experimental
Arm Name:Single Arm
Description:Apremilast 30mg orally twice daily for 16 weeks, sixteen weeks on active study. Post treatment follow-up period of 8 weeks, in the Treatment of Subjects with Severe Recurrent Aphthous Stomatitis (RAS)

Study Agencies

Agency Class:Other
Agency Type:Lead Sponsor
Agency Name:Mayo Clinic
Agency Class:Industry
Agency Type:Collaborator
Agency Name:Celgene

Sample and Retention Information

There are no available Sample and Retention Information

Study References

There are no available Study References

Data Source: ClinicalTrials.gov

Date Processed: August 31, 2019

Modifications to this listing: Only selected fields are shown, please use the link below to view all information about this clinical trial.

If you would like to be contacted by the clinical trial representative please fill out the form below.